China Pharma Holdings, Inc.
CPHI · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $4,529 | $7,011 | $8,104 | $9,642 |
| % Growth | -35.4% | -13.5% | -15.9% | – |
| Cost of Goods Sold | $6,515 | $7,292 | $8,598 | $9,293 |
| Gross Profit | -$1,986 | -$281 | -$494 | $349 |
| % Margin | -43.8% | -4% | -6.1% | 3.6% |
| R&D Expenses | $284 | $240 | $186 | $319 |
| G&A Expenses | $1,785 | $1,466 | $1,893 | $1,651 |
| SG&A Expenses | $2,314 | $2,246 | $2,963 | $3,146 |
| Sales & Mktg Exp. | $529 | $780 | $1,070 | $1,495 |
| Other Operating Expenses | $6 | -$16 | -$94 | -$255 |
| Operating Expenses | $2,603 | $2,471 | $3,055 | $3,210 |
| Operating Income | -$4,589 | -$2,752 | -$3,549 | -$2,861 |
| % Margin | -101.3% | -39.2% | -43.8% | -29.7% |
| Other Income/Exp. Net | -$147 | -$327 | -$424 | -$539 |
| Pre-Tax Income | -$4,736 | -$3,079 | -$3,973 | -$3,399 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,736 | -$3,079 | -$3,973 | -$3,399 |
| % Margin | -104.6% | -43.9% | -49% | -35.3% |
| EPS | -0.27 | -0.29 | -1.94 | -0.85 |
| % Growth | 6.9% | 85.1% | -128.2% | – |
| EPS Diluted | -0.27 | -0.29 | -1.94 | -0.85 |
| Weighted Avg Shares Out | 17,464 | 10,599 | 5,257 | 4,613 |
| Weighted Avg Shares Out Dil | 17,464 | 10,599 | 5,257 | 4,613 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $7 | $11 | $3 |
| Interest Expense | $154 | $334 | $435 | $542 |
| Depreciation & Amortization | $2,618 | $2,754 | $2,701 | $3,088 |
| EBITDA | -$1,964 | $8 | -$838 | $230 |
| % Margin | -43.4% | 0.1% | -10.3% | 2.4% |